CGM

Global Diabetes Care Devices Market Analysis/Forecasts Report 2022: A $42 Billion Market by 2028 - Rapid Technological Advancements in Diabetes Care Devices - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth

Key Points: 
  • However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth
    Technological advancements in the healthcare industry are encouraging market players to focus on research and development of insulin delivery devices.
  • The continuous research in insulin pens supports the growth of the global diabetes care devices market during the forecast period.
  • The diabetes care devices allow diabetes patients to monitor and manage their diabetes in their homes.
  • The prevalence of type 1 diabetes patients is likely to fuel the demand for diabetes care devices.

The Worldwide Next Generation Diabetes Therapy and Drug Delivery Industry is Expected to Reach $28 Million by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region.

Key Points: 
  • The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the next generation diabetes therapy and drug delivery market analysis from 2020 to 2030 to identify the prevailing next generation diabetes therapy and drug delivery market opportunities.
  • In-depth analysis of the next generation diabetes therapy and drug delivery market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global next generation diabetes therapy and drug delivery market trends, key players, market segments, application areas, and market growth strategies.

ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

Retrieved on: 
Thursday, September 22, 2022

Specifically, the grant will fund development of the device for the treatment of hypoglycemia.

Key Points: 
  • Specifically, the grant will fund development of the device for the treatment of hypoglycemia.
  • The ReShape DBSN utilizes hypoglycemia vagal nerve stimulation (HVNS) using an implantable pulse generator (IPG) in a closed loop with a continuous glucose monitor (CGM).
  • The technology has demonstrated safety and efficacy through experiments in diabetic swine utilizing a previous Phase I funding from a NIH SBIR grant.
  • The award of our second NIH SBIR grant is a testament to the strength of the commercial opportunity of our novel DBSN device to address the significant, global diabetes market, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.

Cegedim: Release of 2022 Half-Year Financial Report

Retrieved on: 
Tuesday, September 20, 2022

Cegedim , an innovative technology and services company, announces that its Financial report for the 1st Half of 2022 is available free of charge in French and -in a few days time- in English (that is a free translation into English of the Interim Financial Report 2022 issued in French):

Key Points: 
  • Cegedim , an innovative technology and services company, announces that its Financial report for the 1st Half of 2022 is available free of charge in French and -in a few days time- in English (that is a free translation into English of the Interim Financial Report 2022 issued in French):
    Founded in 1969, Cegedim is an innovative technology and services company in the field of digital data flow management for healthcare ecosystems and B2B, and a business software publisher for healthcare and insurance professionals.
  • Cegedim employs more than 5,600 people in more than 10 countries and generated revenue of 525 million in 2021.
  • Cegedim SA is listed in Paris (EURONEXT: CGM).

Cegedim: 1H 2022 Earnings

Retrieved on: 
Tuesday, September 20, 2022

The Data & marketing division posted like-for-like revenue growth of 11.8% in the first half of 2022.

Key Points: 
  • The Data & marketing division posted like-for-like revenue growth of 11.8% in the first half of 2022.
  • (1) Alternative performance indicator, for a definition and reconciliation of these figures, see point 3.6, note 2 of the 2022 Interim Financial Report.
  • On May 16, 2022, Cegedim Group and social protection companies Malakoff Humanis, Groupe VYV, and PRO BTP Groupe announced that they had finalized the strategic partnership they began negotiating on March 1, 2022.
  • 0.5 per share) in respect of fiscal year 2021 was approved at the General Shareholders Meeting on June 17, 2022, and paid in July 2022.

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

Retrieved on: 
Tuesday, September 20, 2022

Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and help protect against high and low glucose levels 1.

Key Points: 
  • Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and help protect against high and low glucose levels 1.
  • The system then increases, decreases, or pauses insulin delivery based on the users desired and customized glucose target.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • Insulets latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections and zero fingersticks3.

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

Retrieved on: 
Monday, September 19, 2022

Though congenital hyperinsulinism is an incredibly challenging disease to manage, the efficacy and safety of dasiglucagon observed in this Phase 3 trial, support its potential as a new treatment option for children with CHI.

Key Points: 
  • Though congenital hyperinsulinism is an incredibly challenging disease to manage, the efficacy and safety of dasiglucagon observed in this Phase 3 trial, support its potential as a new treatment option for children with CHI.
  • We are very pleased to present the compelling results from the Phase 3 study of dasiglucagon in newborns and infants up to 12 months of age at ESPE 2022.
  • This study deepens our understanding of dasiglucagons potential as an innovative treatment for CHI patients, said David Kendall, M.D., Chief Medical Officer of Zealand Pharma.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress

Retrieved on: 
Thursday, September 15, 2022

REDWOOD CITY, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2022.

Key Points: 
  • Research and development (R&D) expenses were $8.6 million for the fourth quarter of fiscal 2022, compared to $4.4 million for the same period in fiscal 2021.
  • General and administrative (G&A) expenses were $2.7 million for the fourth quarter of fiscal 2022, compared to $2.2 million for the same period in fiscal 2021.
  • Net loss was $9.4 million for the fourth quarter of fiscal 2022, compared to $6.5 million for the same period in fiscal 2021.
  • Full year fiscal 2022 net loss was $41.1 million compared to net loss of $20.9 million for the fiscal year 2021.

Global Smart Insulin Pens Market Report 2022-2026 & 2031 Featuring Key Players - Eli Lilly and Company; Novo Nordisk A/S; Diamesco Co. Ltd.; Emperra GmbH E-Health Technologies - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022

The smart insulin pens market consists of sales of smart insulin pens which allows to dial the insulin dose accurately and related products.

Key Points: 
  • The smart insulin pens market consists of sales of smart insulin pens which allows to dial the insulin dose accurately and related products.
  • The smart insulin pens are injector pens with the needle that help people with diabetes to manage insulin delivery.
  • The main types of smart insulin pens are first-generation pens and second-generation pens (Bluetooth enabled, USB connected).
  • The second-generation smart insulin pens are devices that are engineered with Bluetooth or USB features to enable closer monitoring.

Chubb Announces Alex Jackson as Product Head of Management Liability for Global Markets

Retrieved on: 
Monday, September 12, 2022

LONDON, Sept. 12, 2022 /PRNewswire/ -- Chubb today announced the appointment of Alex Jackson as Product Head of Management Liability for Chubb Global Markets (CGM), the company's London Market wholesale and specialty business including its Lloyd's platform.

Key Points: 
  • LONDON, Sept. 12, 2022 /PRNewswire/ -- Chubb today announced the appointment of Alex Jackson as Product Head of Management Liability for Chubb Global Markets (CGM), the company's London Market wholesale and specialty business including its Lloyd's platform.
  • Previously Senior Underwriter within the CGM Management Liability team, Alex will now lead all aspects of CGM's Management Liability business.
  • He will continue to be based in London and report to Robert Wilson, Chief Underwriting Officer for Chubb Global Markets and Active Underwriter of Chubb's Lloyd's Syndicate 2488.
  • Robert Wilson said: "I am delighted that we are able to promote Alex to this important role within Chubb Global Markets.